Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

Status unconfirmed · Phase 1

Conditions studied: Solid Tumors

In brief

An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)

Key facts

Study ID

NCT00688116

Run by

Synta Pharmaceuticals Corp.

People needed

45

Starts

2007-10-01

Expected to finish

2014-11-01

Last updated by the study team

2014-09-18

Who can join

Age: 25 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be documented to be refractory or not candidates for current approved therapies. - Must have anECOG status 0-2. - Peripheral neuropathy ?2.
• Must have acceptable organ and marrow function per protocol parameters.
• No clinically significant ventricular arrythmias or ischemia.

You may not qualify if…

• Must not be pregnant or breastfeeding. -No chemotherapy or radiation within 3 weeks..
• No previous radiation to >25% of total bone marrow.
• No previous high dose chemotherapy with autologous or allogeniec hematopoietic stem cell transplantation.
• No primary brain tumors or active brain metastases.
• No use of any investigational agents within 4 weeks.
• No treatment with chronic immunosuppressants.
• No uncontrolled, intercurrent illness.

Where it is running

• UCLA — Los Angeles, California, United States
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center (BIDMC) - Cancer Center — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Wayne State University/Karmanos Cancer Institute — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.